Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report

Peripheral T-cell lymphoma (PTCL) represents a small heterogeneous group of non-Hodgkin lymphoma (NHL) that accounts for ~10% of NHLs in western countries and ~25% of NHLs in Japan. The disease remains extremely difficult to treat. Therefore, novel treatment modalities are required. Mogamulizumab is...

Descripción completa

Detalles Bibliográficos
Autores principales: FUJITA, YUKIE, NAKAYA, AYA, FUJITA, SHINYA, HOTTA, MASAAKI, YOSHIMURA, HIDEAKI, AZUMA, YOSHIKO, NAKANISHI, TAKAHISA, SATAKE, ATSUSHI, ISHII, KAZUYOSHI, ITO, TOMOKI, NOMURA, SHOSAKU
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734048/
https://www.ncbi.nlm.nih.gov/pubmed/26893851
http://dx.doi.org/10.3892/mco.2015.695
Descripción
Sumario:Peripheral T-cell lymphoma (PTCL) represents a small heterogeneous group of non-Hodgkin lymphoma (NHL) that accounts for ~10% of NHLs in western countries and ~25% of NHLs in Japan. The disease remains extremely difficult to treat. Therefore, novel treatment modalities are required. Mogamulizumab is a humanized immunoglobulin G1 monoclonal antibody that targets CC chemokine receptor 4. To the best of our knowledge, the efficacy of mogamulizumab in patients who are refractory to conventional chemotherapy following autologous stem cell transplantation has not been investigated previously. The present study reports a patient with PTCL who relapsed following autologous stem cell transplantation and became resistant to salvage chemotherapy, in whom mogamulizumab showed evident efficacy without severe adverse event.

Ejemplares similares